PhD Thesis_ver3.pdf

323
VII. Библиография
228. Sakano, K. and S. Kawanishi (2002). "Metal-mediated DNA damage induced by curcumin in the
presence of human cytochrome P450 isozymes." Arch Biochem Biophys 405(2): 223-30.
229. San-Miguel, J. F. and M. V. Mateos (2009). "How to treat a newly diagnosed young patient with
multiple myeloma." Hematology Am Soc Hematol Educ Program: 555-65.
230. Scaffidi, C., S. Fulda, A. Srinivasan, C. Friesen, F. Li, et al. (1998). "Two CD95 (APO-1/Fas)
signaling pathways." EMBO J 17(6): 1675-87.
231. Seidel, C., A. Sundan, M. Hjorth, I. Turesson, I. M. Dahl, et al. (2000). "Serum syndecan-1: a new
independent prognostic marker in multiple myeloma." Blood 95(2): 388-92.
232. Sengul, S., C. Zwizinski and V. Batuman (2003). "Role of MAPK pathways in light chain-induced
cytokine production in human proximal tubule cells." Am J Physiol Renal Physiol 284(6):
F1245-54.
233. Shinkai, Y., D. Sumi, T. Toyama, T. Kaji and Y. Kumagai (2009). "Role of aquaporin 9 in cellular
accumulation of arsenic and its cytotoxicity in primary mouse hepatocytes." Toxicol Appl
Pharmacol 237(2): 232-6.
234. Smadja, N. V., C. Bastard, C. Brigaudeau, D. Leroux and C. Fruchart (2001). "Hypodiploidy is a
major prognostic factor in multiple myeloma." Blood 98(7): 2229-38.
235. Smadja, N. V., C. Fruchart, F. Isnard, C. Louvet, J. L. Dutel, et al. (1998). "Chromosomal analysis in
multiple myeloma: cytogenetic evidence of two different diseases." Leukemia 12(6): 960-9.
236. Smith, P. K., R. I. Krohn, G. T. Hermanson, A. K. Mallia, F. H. Gartner, et al. (1985).
"Measurement of protein using bicinchoninic acid." Anal Biochem 150(1): 76-85.
237. Sobottka, S. B., M. R. Berger and H. Eibl (1993). "Structure-activity relationships of four anticancer
alkylphosphocholine derivatives in vitro and in vivo." Int J Cancer 53(3): 418-25.
238. Song, L., Y. Li, Y. X. Sun, M. Yu and B. F. Shen (2002). "IL-6 inhibits apoptosis of human myeloma
cell line XG-7 through activation of JAK/STAT pathway and up-regulation of Mcl-1." Ai Zheng
21(2): 113-6.
239. Stekar, J., P. Hilgard and T. Klenner (1995). "Opposite effect of miltefosine on the antineoplastic
activity and haematological toxicity of cyclophosphamide." Eur J Cancer 31A(3): 372-4.
240. Stephanou, A., B. K. Brar, R. A. Knight and D. S. Latchman (2000). "Opposing actions of STAT-1
and STAT-3 on the Bcl-2 and Bcl-x promoters." Cell Death Differ 7(3): 329-30.
241. Stewart, A. K. (2009). "Novel therapies for relapsed myeloma." Hematology Am Soc Hematol
Educ Program: 578-86.
242. Sumi, D., Y. Shinkai and Y. Kumagai (2010). "Signal transduction pathways and transcription
factors triggered by arsenic trioxide in leukemia cells." Toxicol Appl Pharmacol 244(3): 385-
92.
243. Sung, B., A. B. Kunnumakkara, G. Sethi, P. Anand, S. Guha, et al. (2009). "Curcumin circumvents
chemoresistance in vitro and potentiates the effect of thalidomide and bortezomib against
human multiple myeloma in nude mice model." Mol Cancer Ther 8(4): 959-70.
244. Sydor, J. R., E. Normant, C. S. Pien, J. R. Porter, J. Ge, et al. (2006). "Development of 17allylamino-17-demethoxygeldanamycin
hydroquinone hydrochloride (IPI-504), an anti-cancer
agent directed against Hsp90." Proc Natl Acad Sci U S A 103(46): 17408-13.
245. Tai, Y. T., M. Fulciniti, T. Hideshima, W. Song, M. Leiba, et al. (2007). "Targeting MEK induces
myeloma-cell cytotoxicity and inhibits osteoclastogenesis." Blood 110(5): 1656-63.
246. Thomas, A., T. Trarbach, C. Bartel, D. Laurent, A. Henry, et al. (2007). "A phase IB, open-label
dose-escalating study of the oral angiogenesis inhibitor PTK787/ZK 222584 (PTK/ZK), in
combination with FOLFOX4 chemotherapy in patients with advanced colorectal cancer." Ann
Oncol 18(4): 782-8.
247. Tian, E., F. Zhan, R. Walker, E. Rasmussen, Y. Ma, et al. (2003). "The role of the Wnt-signaling
antagonist DKK1 in the development of osteolytic lesions in multiple myeloma." N Engl J Med
349(26): 2483-94.
248. Tolcher, A. W., M. Mita, N. J. Meropol, M. von Mehren, A. Patnaik, et al. (2007). "Phase I
pharmacokinetic and biologic correlative study of mapatumumab, a fully human monoclonal